Prime Medicine (NASDAQ:PRME – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright‘s target price suggests a potential upside of 87.35% from the company’s current price.
PRME has been the topic of several other reports. Jefferies Financial Group reaffirmed a “market outperform” rating on shares of Prime Medicine in a research note on Monday, September 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of Prime Medicine in a research report on Monday, August 31st. Wall Street Zen upgraded shares of Prime Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, October 31st. Citigroup restated a “market outperform” rating on shares of Prime Medicine in a research note on Friday, September 25th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $7.00 price objective on shares of Prime Medicine in a research report on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $7.86.
View Our Latest Stock Analysis on Prime Medicine
Prime Medicine Stock Performance
Prime Medicine (NASDAQ:PRME – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. The business had revenue of $4.21 million during the quarter. Prime Medicine had a negative net margin of 2,497.56% and a negative return on equity of 222.88%. On average, sell-side analysts predict that Prime Medicine will post -0.97 earnings per share for the current year.
Hedge Funds Weigh In On Prime Medicine
A number of institutional investors and hedge funds have recently made changes to their positions in PRME. Arizona State Retirement System increased its holdings in shares of Prime Medicine by 15.5% in the 2nd quarter. Arizona State Retirement System now owns 28,646 shares of the company’s stock valued at $106,000 after acquiring an additional 3,855 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Prime Medicine by 15.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 33,094 shares of the company’s stock worth $102,000 after purchasing an additional 4,349 shares during the last quarter. Royal Bank of Canada boosted its holdings in Prime Medicine by 89.3% in the first quarter. Royal Bank of Canada now owns 9,254 shares of the company’s stock valued at $32,000 after purchasing an additional 4,365 shares in the last quarter. Swiss National Bank boosted its holdings in Prime Medicine by 5.0% in the first quarter. Swiss National Bank now owns 178,600 shares of the company’s stock valued at $622,000 after purchasing an additional 8,500 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Prime Medicine in the third quarter valued at approximately $28,000. 70.37% of the stock is owned by institutional investors and hedge funds.
Prime Medicine Company Profile
Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.
See Also
- Five stocks we like better than Prime Medicine
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
